Boston Scientific vs 3m (BSX vs MMM)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
3m is the larger company by revenue ($24.9B vs $20.1B) and market value ($82.3B vs $66.5B). Boston Scientific has grown revenue faster over the last 4 fiscal years (+68.9% cumulative vs -29.4%). Boston Scientific trades at the lower trailing P/E (18.7x vs 30.4x).
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties. Its products include minimally invasive devices for diagnosing and treating cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions. The company serves physicians and medical professionals worldwide by providing technologies such as endoscopy tools, urology devices, neuromodulation systems, cardiovascular therapies, and electrophysiology equipment.
About 3m
3M Company is a diversified technology firm operating globally in three main segments: Safety and Industrial, Transportation and Electronics, and Consumer. It manufactures a wide range of products including abrasives, adhesives, personal safety equipment, electronic materials, home care items, and office supplies. The company serves various markets such as industrial, automotive, aerospace, electronics, and consumer goods through multiple distribution channels worldwide.
Head to head (BSX FY2025 vs MMM FY2025)
| Metric | BSXFY2025 | MMMFY2025 |
|---|---|---|
| Revenue | $20.07B | $24.95B |
| Revenue growth (YoY) | 19.9% | 1.5% |
| Gross margin | 69.0% | 39.9% |
| Operating margin | 18.0% | 18.6% |
| Net margin | 14.4% | 13.0% |
| Net income | $2.89B | $3.25B |
| Diluted EPS | $1.94 | $6.00 |
| FCF margin | 18.2% | 5.6% |
| ROE | 11.8% | 68.5% |
| Debt / equity | 0.5× | 2.3× |
| Market cap | $66.54B | $82.25B |
| P/E (TTM) | 18.7× | 30.4× |
Fundamentals are from each company’s SEC filings (BSX FY2025, MMM FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| BSX | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B |
| MMM | $35.35B | $26.16B | $24.61B | $24.57B | $24.95B |
Peer standing
Where each company ranks among the 88 medical device companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | BSX | MMM |
|---|---|---|
| Gross margin | 69.0%64th percentile of 77 | 39.9%17th percentile of 77 |
| Operating margin | 18.0%87th percentile of 80 | 18.6%89th percentile of 80 |
| Net margin | 14.4%86th percentile of 81 | 13.0%84th percentile of 81 |
| FCF margin | 18.2%88th percentile of 74 | 5.6%66th percentile of 74 |
| Revenue growth (YoY) | +19.9%70th percentile of 87 | +1.5%22nd percentile of 87 |
| ROE | 11.8%78th percentile of 79 | 68.5%97th percentile of 79 |
| P/E (TTM) | 18.7×23rd percentile of 32 | 30.4×48th percentile of 32 |
| Debt / equity | 0.46×45th percentile of 54 | 2.30×87th percentile of 54 |
| Short interest (days to cover) | 1.19d15th percentile of 88 | 2.32d29th percentile of 88 |
Short interest
| FINRA settlement data | BSX | MMM |
|---|---|---|
| Shares sold short | 27.9M | 9.8M |
| Change vs prior settlement | -6.1% | -16.5% |
| Days to cover | 1.19 | 2.32 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | BSX | MMM |
|---|---|---|
| Buys | 4 ($553,999) | — |
| Sells | 0 | — |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
9 tracked 13F managers hold both Boston Scientific and 3m as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Dodge & Cox, Gotham Asset Management, Millennium Management, Renaissance Technologies, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
BDX vs BSXBSX vs DXCMBSX vs MDLNBSX vs RMDBSX vs SYKBSX vs WSTAll medical device stocks →All comparisons →
Track BSX and MMM
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.